Fennec Pharmaceuticals to Participate in Upcoming Investor Conferences
Rhea-AI Summary
Fennec Pharmaceuticals (NASDAQ:FENC; TSX: FRX), a commercial stage specialty pharmaceutical company, has announced its participation in two upcoming investor conferences. The company will be presenting at the H.C. Wainwright Global Investment Conference on September 11, 2024, from 12:00 p.m. to 12:30 p.m. ET in New York City. Additionally, Fennec will participate in a fireside chat at the Cantor Fitzgerald Global Healthcare Conference on September 19, 2024, from 8:35 a.m. to 9:05 a.m. ET, also in New York City.
The management team will be available for one-on-one investor meetings at both conferences. Investors can find additional information about these events on the company's website in the investor relations section.
Positive
- None.
Negative
- None.
News Market Reaction
On the day this news was published, FENC declined 3.42%, reflecting a moderate negative market reaction.
Data tracked by StockTitan Argus on the day of publication.
RESEARCH TRIANGLE PARK, N.C., Sept. 05, 2024 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (NASDAQ:FENC; TSX: FRX), a commercial stage specialty pharmaceutical company, today announced that the Company will be participating in upcoming investor conferences. The management team will also host one-on-one investor meetings at the conferences.
Conference Details:
Event: H.C. Wainwright Global Investment Conference
Date: September 11, 2024
Time: Company Presentation at 12:00 p.m. – 12:30 p.m. ET
Location: New York City, Lotte NY Palace Hotel, Holmes 1, 4th Floor
Event: Cantor Fitzgerald Global Healthcare Conference
Date: September 19, 2024
Time: Fireside Chat at 8:35 a.m. – 9:05 a.m. ET
Location: New York City, InterContinental Barclay Hotel, Track 3, Grand Ballroom 1
For additional information, please visit the investor relations section of the Company’s website at:
https://investors.fennecpharma.com/events-and-presentations/events.
About Fennec Pharmaceuticals
Fennec Pharmaceuticals Inc. is a specialty pharmaceutical company focused on the development and commercialization of PEDMARK® to reduce the risk of platinum-induced ototoxicity in pediatric patients. Further, PEDMARK received FDA approval in September 2022 and European Commission approval in June 2023 and U.K. approval in October 2023 under the brand name PEDMARQSI. PEDMARK has received Orphan Drug Exclusivity in the U.S. and PEDMARQSI has received Pediatric Use Marketing Authorization in Europe, which includes eight years plus two years of data and market protection. For more information, please visit www.fennecpharma.com.
For further information, please contact:
Investors:
Robert Andrade
Chief Financial Officer
Fennec Pharmaceuticals Inc.
+1 919-246-5299
Corporate & Media:
Lindsay Rocco
Elixir Health Public Relations
+1 862-596-1304
lrocco@elixirhealthpr.com
FAQ
When is Fennec Pharmaceuticals (FENC) presenting at the H.C. Wainwright Global Investment Conference?
Where is the Cantor Fitzgerald Global Healthcare Conference being held for Fennec Pharmaceuticals (FENC)?
What type of session will Fennec Pharmaceuticals (FENC) have at the Cantor Fitzgerald Global Healthcare Conference?
Will Fennec Pharmaceuticals (FENC) management be available for one-on-one meetings at these conferences?
Where can investors find more information about Fennec Pharmaceuticals' (FENC) conference participation?
